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Abstract
Background: As the average age of the HIV-positive population increases, there is increasing need to monitor
patients for the development of comorbidities as well as for drug toxicities.
Methods: We examined factors associated with the frequency of measurement of liver enzymes, renal function
tests, and lipid levels among participants of the Canadian Observational Cohort (CANOC) collaboration which
follows people who initiated HIV antiretroviral therapy in 2000 or later. We used zero-inflated negative binomial
regression models to examine the associations of demographic and clinical characteristics with the rates of
measurement during follow-up. Generalized estimating equations with a logit link were used to examine factors
associated with gaps of 12 months or more between measurements.
Results: Electronic laboratory data were available for 3940 of 7718 CANOC participants. The median duration of
electronic follow-up was 3.5 years. The median (interquartile) rates of tests per year were 2.76 (1.60, 3.73), 2.55
(1.44, 3.38) and 1.42 (0.50, 2.52) for liver, renal and lipid parameters, respectively. In multivariable zero-inflated
negative binomial regression models, individuals infected through injection drug use (IDU) were significantly
less likely to have any measurements. Among participants with at least one measurement, rates of measurement of
liver, renal and lipid tests were significantly lower for younger individuals and Aboriginal Peoples. Hepatitis
C co-infected individuals with a history of IDU had lower rates of measurement and were at greater risk of
having 12 month gaps between measurements.
Conclusions: Hepatitis C co-infected participants infected through IDU were at increased risk of gaps in testing, despite
publicly funded health care and increased risk of comorbid conditions. This should be taken into consideration in analyses
examining factors associated with outcomes based on laboratory parameters.
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Background
Comorbidities are of particular concern in HIV-positive
populations as successful treatment of HIV with com-
bination antiretroviral therapy (cART) and increased
incident HIV infection in older individuals have led to
an increase in the average age of HIV-positive popula-
tions [1, 2]. Laboratory measurement of liver enzymes,
renal function, and lipid levels in HIV-positive individ-
uals is essential for detecting early development of such
comorbidities, and for identification of treatment-related
toxicities and adverse interactions between antiretroviral
and non-antiretroviral medications [3].
The recommended frequency of laboratory assessment
after cART initiation varies among HIV treatment guide-
lines [4–7]. To monitor for potential toxicity related to
cART, all guidelines recommend laboratory assessment
of liver enzymes, renal function, and lipid levels at entry
to care and prior to initiation of cART, and at least
annually thereafter. The Department of Health and Hu-
man Services (DHHS) [4] and British HIV Association
(BHIVA) [6] recommend the most frequent monitoring
of liver enzymes, at least every 3-6 months. The British
Columbia Centre for Excellence in HIV/AIDS (BC CfE)
[7] recommends the most frequent monitoring of renal
function, every 3-4 months.
Risk factors and clinical features also influence the
recommended frequency of testing within the guidelines.
For instance, BHIVA recommends more frequent meas-
urement of lipid levels for patients at high risk of
cardiovascular disease [6, 8]. Similarly, European AIDS
Clinical Society (EACS) and BC CfE guidelines suggest
more frequent monitoring of liver enzymes and renal
function for patients taking hepatotoxic or nephrotoxic
drugs, or patients with elevated risk of liver or kidney
disease due to factors such as hepatitis C co-infection
and diabetes [5, 9].
We conducted this analysis to determine whether
demographic and clinical characteristics were associated
with rates of laboratory testing and clinically significant
gaps in measurement of liver enzymes, renal function,
and lipid tests among individuals who initiated cART
since January 1, 2000 in Canada. The motivation for this
work was primarily to determine if HIV-positive individ-
uals were accessing services equitably within a publicly
funded health care system and, secondly, to determine
whether there was evidence of measurement bias that
could aid in interpretation of analyses of HIV co-
morbidities that rely upon routinely collected laboratory
marker data.
Methods
Study population
The Canadian Observational Cohort (CANOC) is a
national collaboration of eight cohorts of antiretroviral-
naive HIV-positive individuals initiating cART after
January 1, 2000 from three Canadian provinces (British
Columbia (BC), Quebec, and Ontario). The study design
has been reported previously [10]. Briefly, to be eligible
for CANOC, patients must have documented HIV infec-
tion, reside in Canada, be at least 18 years of age, initiate
their first antiretroviral regimen comprised of at least
three agents, and have at least one measurement of HIV
plasma viral load and CD4 cell count within six months
of initiating cART. Individuals under follow-up at sites
and for time periods with electronic laboratory data
were included in this analysis. Time periods for which
electronic laboratory data were available for each site
were determined through consultation with site investi-
gators. Patient selection and data extraction were
performed locally at the data centers of the participat-
ing cohort studies. Sites were instructed to provide all
available data on a predefined set of demographic,
laboratory, and clinical variables. Non-nominal data
from each cohort were then pooled at the Project Data
Centre in Vancouver, BC.
Ethics statement
The human subjects activities of CANOC have been
approved by the Simon Fraser University Research Eth-
ics Board (REB) and the University of British Columbia
REB. Additionally, approval from local institutional
review boards (IRBs) was granted at each participating
cohort site, as follows: Providence Health Care Research
Institute Office of Research Services, the Ottawa Hos-
pital REB, University Health Network (UHN) REB,
Véritas IRB, Biomedical C REB of the McGill University
Heath Centre (MUHC), University of Toronto HIV REB,
and Women’s College Hospital REB.
Local cohorts have obtained written consent from
participants with the following exceptions: HAART Ob-
servational Medical Evaluation and Research (HOMER)
Cohort (IRB approves the retrospective use of anonym-
ous administrative data without requiring consent; an
information sheet is provided in lieu of a consent form);
Ottawa Hospital Cohort (IRB approves the anonymous
use of data retrospectively abstracted from clinical care
databases without requiring consent); UHN (REB ap-
proves the anonymous use of data retrospectively
abstracted from clinical care databases without requiring
consent); MUHC (IRB approves the anonymous use of
data retrospectively abstracted from clinical care data-
bases without requiring consent; patients sign a general
waiver on opening a medical chart at the hospital but no
specific study related consent); Maple Leaf Medical
Clinic (REB has approved the anonymous use of data
retrospectively abstracted from clinical care databases
without requiring consent); Electronic Antiretroviral
Therapy (EARTH) Cohort (REB approves the anonymous
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use of data retrospectively abstracted from clinical care
databases without requiring consent; patients sign a
general waiver on opening a medical chart at the hospital
but no specific study related consent).
Outcome measures
The three sets of laboratory measurements studied were
(a) the liver enzymes alanine transaminase (ALT) or aspar-
tate transaminase (AST), (b) creatinine, as a measure of
renal function, and (c) at least one of the following
measures of lipid levels: LDL or HDL cholesterol, triglyc-
erides or total cholesterol. For each set of measurements,
we determined the rate of measurement per year (i.e., the
number of tests per person-year of observation) and
whether the gaps between pairs of consecutive measure-
ments exceeded 12 months, which was considered to be a
clinically important gap between measurements. To avoid
inflated rates of measurement from testing during appar-
ent hospitalization or intensive monitoring during changes
in cART or other therapies (e.g. for hepatitis C virus),
repeat measurements within 30 days were excluded from
determination of the rates of measurement.
Explanatory variables of interest
We selected potential prognostic factors for laboratory
testing based on a priori knowledge of associations with
frequency of clinical follow-up. We examined demo-
graphic and clinical characteristics including age, sex,
province, race, HIV risk factors such as injection drug
use (IDU) and men having sex with men (MSM), year of
first HIV positive test, co-infection with hepatitis B or C,
CD4 count and HIV viral load at cART initiation, and
class of ARV in the initial cART regimen. Grade 3 or 4
elevations for each laboratory measure were defined as
follows: AST (5 times upper limit normal (ULN) = 170
units per litre (U/L)), ALT (5 times ULN = 200 U/L),
creatinine (3 times ULN = 330 μmol/L for men,
294 μmol/L for women), LDL (5.0 mmol/L), triglyceride
(8.48 mmol/L), total cholesterol (7.78 mmol/L) and total
cholesterol/HDL ratio (7.0).
Statistical analysis
Demographic and clinical characteristics were summa-
rized for participants who were included and excluded
from the analysis using frequencies and percentages
for categorical variables and medians and interquartile
ranges for continuous variables. Chi square tests,
Cochran-Armitage tests for trend and Wilcoxon rank
sum tests were used to compare rates of measure-
ment and the probability of a gap among subgroups
of participants according to demographic or clinical
characteristics.
Zero-inflated negative binomial regression models
were used to examine the associations of demographic
and clinical characteristics with the rates of measure-
ment of ALT/AST, creatinine, and lipids during follow-
up. The negative binomial distribution accounts for
overdispersion in the distribution of the number of
laboratory tests relative to a Poisson distribution, while a
zero-inflated model allows for the explicit modeling of
the probability of having no laboratory tests. Generalized
estimating equation (GEE) models with a logit link were
used to examine factors associated with a 12 month gap
between sequential measurements. An unstructured
correlation matrix was used to account for correlation
among repeat observations within individuals. Time-
updated variables were used to model the associations of
CD4 counts, HIV viral load and grade 3 or 4 elevations
of laboratory markers with a 12 month gap between
measurements. Sensitivity analyses were conducted with
an 18 month gap between measurements. For variables
with large amounts of missing data, separate categories
were created for missing values. All analyses were
conducted with SAS 9.4 (SAS Institute, Cary, North
Carolina, USA).
Results
A total of 7718 participants were enrolled into CANOC
as of September 2011, of whom 3940 were followed
during calendar time periods when electronic laboratory
data were available at their site. Clinical and demo-
graphic characteristics are described for all patients and
by availability of electronic laboratory data in Table 1.
The median duration of electronic laboratory follow-up
was 3.5 (IQR 2.0, 6.1) years. The median age was
39 years, 83 % were male, 58 % were men who have sex
with men (MSM), 17 % were IDU and 18 % were co-
infected with hepatitis C.
Ninety-three percent of participants for whom elec-
tronic laboratory data were available had at least one
ALT/AST measurement; the median rate of measure-
ment of ALT/AST per year of follow-up was 2.8 (IQR
1.6, 3.7). The rate of measurement differed by province,
gender, age, race, HIV risk factor, baseline regimen, and
IDU history and hepatitis C co-infection (Table 2).
Hepatitis C co-infected participants with a history of
IDU had a lower rate of ALT/AST measurement than
other participants (median of 1.83 versus 2.89,3.31, and
2.90 for HCV- non-IDU participants, HCV+ non-IDUs
and HCV- IDUs respectively, p < 0.0001, Table 2). In the
multivariable zero-inflated negative binomial regression
model, a history of IDU was significantly associated with
a lower probability of having at least one ALT/AST meas-
urement while under follow-up (odds ratio, OR = 0.19,
95 % confidence interval (CI) = (0.11, 0.32), p < 0.0001).
Among participants with at least one measure of
ALT/AST, Aboriginal ancestry was associated with
lower rates of measurement (rate ratio (RR) =0.87,
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95 % CI = (0.79, 0.96), p < 0.01), as was hepatitis C
co-infection among participants with a history of IDU
(RR = 0.79, 95 % CI = (0.74, 0.83), p < 0.0001) relative
to HIV mono-infected non-IDUs. Increasing age (RR
per 10 years =1.02, 95 % CI = (1.00, 1.04), p = 0.03)
was associated with a higher rate of measurement of
ALT/AST.
Ninety percent and 84 % of participants had at least
one measurement of creatinine and lipids, respectively.
The median rates of measurement of creatinine and
lipids per year of follow-up were 2.6 (IQR 1.4, 3.4) and
1.4 (IQR 0.5, 2.5), respectively. Associations of demo-
graphic and clinical variables with rates of creatinine and
lipid measurements were similar to those for liver en-
zymes (Table 3). Participants with a history of IDU were
less likely to have any creatinine or lipid measurements
during the study period (RR = 0.22 and 0.17, respect-
ively). Among participants with at least one creatinine or
Table 1 Characteristics of included and excluded participants due to availability of electronic data
Characteristics Cohort (n = 7718) Included (n = 3940) Excluded (n = 3778)
Province
British Columbia 3588 (46 %) 787 (20 %) 2801 (74 %)
Ontario 2394 (31 %) 1715 (44 %) 679 (18 %)
Quebec 1736 (22 %) 1438 (36 %) 298 (8 %)
Age 40 (34-47) 39 (33-46) 41 (34-48)
Male 6208 (81 %) 3255 (83 %) 2953 (78 %)
Race
Caucasian 2046 (27 %) 1040 (26 %) 1006 (27 %)
Black 512 (7 %) 373 (9 %) 139 (4 %)
Aboriginal 484 (6 %) 117 (3 %) 367 (10 %)
Other 448 (6 %) 285 (7 %) 163 (4 %)
Unknown 4228 (55 %) 2125 (54 %) 2103 (56 %)
HIV Risk factor
Men having sex with men 2758 (49 %) 1877 (58 %) 881 (37 %)
Injection drug use 1766 (31 %) 555 (17 %) 1211 (51 %)
From Endemic Country 684 (12 %) 553 (17 %) 131 (6 %)
Unknown 2100 (27 %) 680 (17 %) 1420 (38 %)
Year of cART initiation
2000 546 (7 %) 271 (7 %) 275 (7 %)
2001-2005 2980 (39 %) 1723 (44 %) 1257 (33 %)
>2005 4192 (54 %) 1946 (49 %) 2246 (59 %)
Baseline cART Regimen
NNRTI-based 3562 (46 %) 1727 (44 %) 1835 (49 %)
Boosted PI-based 3091 (40 %) 1506 (38 %) 1585 (42 %)
Other PI-based 928 (12 %) 611 (16 %) 317 (8 %)
Other 137 (2 %) 96 (2 %) 41 (1 %)
Year of HIV+ Test 2003 (2000-2006) 2003 (2000-2006) 2002 (1998-2005)
Hepatitis C positive 1922 (27 %) 663 (18 %) 1259 (37 %)
Hepatitis B positive 386 (10 %) 304 (11 %) 82 (9 %)
Baseline CD4 (cells/mm3) 210 (110-300) 210 (112-297) 210 (110-310)
>500 cells/mm3 431 (6 %) 164 (4 %) 267 (7 %)
350-500 cells/mm3 970 (13 %) 483 (12 %) 487 (13 %)
200-350 cells/mm3 2745 (36 %) 1444 (37 %) 1301 (34 %)
<200 cells/mm3 3572 (46 %) 1849 (47 %) 1723 (46 %)
Baseline Viral Load (log10 copies/mL) 4.9 (4.3-5.1) 4.9 (4.4-5.2) 4.8 (4.2-5.0)
Results are presented as median (interquartile range) or N (%)
Gillis et al. BMC Infectious Diseases  (2015) 15:453 Page 4 of 10
Table 2 Median rate of measurement and probability of having a gap greater than 12 months between measurements of liver,
renal or metabolic function
Liver (AST/ALT) Renal (Creatinine) Metabolic (Lipids)
Annual rate of testing,
Median (IQR)
Subjects with≥ 1
12-month gap
Annual rate of
testing, Median (IQR)
Subjects with≥ 1
12-month gap
Annual rate of
testing, Median (IQR)
Subjects with≥
1 12-month gap
Overall 2.76 (1.60,3.73) 22 % 2.55 (1.44,3.38) 18 % 1.42 (0.50,2.52) 33 %
First year of cART 3 (0, 4) – 2 (0, 4) – 1 (0, 3) –
Subsequent years 2.23 (0.31, 3.41) – 1.78 (0, 3.06) – 0.85 (0, 2.21) –
Region
British Columbia 3.25 (0.82,4.56)*** 33 %*** 1.66 (0.41,3.08)*** 23 %*** 1.05 (0.22,2.70)** 24 %***
Ontario 2.53 (1.37,3.53) 17 % 2.35 (1.33,3.20) 14 % 1.45 (0.50,2.46) 32 %
Quebec 2.88 (2.08,3.56) 21 % 2.88 (2.07,3.56) 17 % 1.48 (0.66,2.53) 38 %
Gender
Male 2.80 (1.65,3.77)* 21 %*** 2.59 (1.47,3.41)** 16 %** 1.49 (0.57,2.60)*** 31 %***
Female 2.60 (1.39,3.56) 29 % 2.33 (1.17,3.28) 24 % 1.02 (0.33,2.09) 43 %
Age
<55 2.73 (1.57,3.71)* 23 %** 2.52 (1.43,3.36)** 18 %** 1.39 (0.49,2.48)** 34 %*
≥55 3.03 (1.92,4.10) 12 % 2.90 (1.83,3.69) 9 % 1.83 (0.79,2.95) 23 %
Race
Caucasian 3.03 (1.43,4.16)*** 24 %*** 2.49 (1.07,3.44)*** 21 %*** 1.64 (0.53,2.85)*** 31 %**
Black 2.73 (1.55,3.74) 26 % 2.27 (1.23,3.17) 18 % 1.01 (0.43,2.09) 45 %
Aboriginal 2.07 (0.51,3.59) 45 % 1.08 (0.28,2.54) 30 % 0.45 (0.12,1.95) 29 %
Other 3.38 (2.39,4.40) 15 % 2.62 (1.72,3.49) 12 % 2.03 (0.75,2.98) 25 %
Unknown 2.64 (1.67,3.43) 20 % 2.63 (1.70,3.39) 16 % 1.41 (0.52,2.34) 34 %
Risk Factor
MSM 2.97 (1.98,3.92)*** 18 %*** 2.72 (1.81,3.48)*** 15 %*** 1.53 (0.61,2.61)*** 32 %**
Non-MSM 2.59 (1.26,3.68) 31 % 2.28 (0.97,3.32) 24 % 1.02 (0.31,2.02) 41 %
IDU 2.13 (0.74,3.66)*** 38 %*** 1.46 (0.41,3.02)*** 29 %*** 0.66 (0.00,1.63)*** 34 %
Non-IDU 2.89 (1.87,3.84) 21 % 2.67 (1.79,3.48) 16 % 1.45 (0.59,2.52) 36 %
Endemic 2.75 (1.83,3.62) 22 % 2.65 (1.87,3.44) 20 % 1.21 (0.57,2.12) 50 %***
Non-Endemic 2.85 (1.63,3.86) 24 % 2.58 (1.42,3.43) 18 % 1.35 (0.46,2.46) 33 %
Unknown Risk Factor 2.40 (1.35,3.34)*** 15 %*** 2.33 (1.34,3.19)** 14 %* 1.91 (0.67,2.91)*** 21 %***
Known Risk Factor 2.83 (1.69,3.81) 23 % 2.59 (1.46,3.43) 18 % 1.32 (0.48,2.41) 35 %
Year of cART Initiation
>2005 2.77 (1.63,3.72) 12 %*** 2.49 (1.21,3.40)* 9 %*** 1.21 (0.33,2.30)*** 23 %***
2001-2005 2.77 (1.60,3.79) 27 % 2.61 (1.66,3.38) 22 % 1.66 (0.63,2.72) 40 %
2000 2.53 (1.36,3.47) 53 % 2.51 (1.34,3.25) 37 % 1.45 (0.57,2.70) 49 %
Baseline CD4 count
<200 cells/mm3 2.83 (1.62,3.78)*** 25 % 2.55 (1.41,3.42)** 19 % 1.44 (0.56,2.59)*** 34 %
200-350 cells/mm3 2.79 (1.71,3.67) 18 % 2.61 (1.59,3.33) 15 % 1.39 (0.52,2.47) 31 %
350-500 cells/mm3 2.66 (1.52,3.75) 21 % 2.50 (1.56,3.49) 17 % 1.48 (0.47,2.56) 31 %
>500 cells/mm3 2.07 (0.82,3.31) 28 % 1.88 (0.00,3.09) 21 % 0.88 (0.00,2.09) 34 %
Baseline Regimen
NNRTI-Based 2.68 (1.57,3.56)** 19 %*** 2.45 (1.36,3.23)* 16 %** 1.30 (0.47,2.34)*** 34 %***
Boosted PI-Based 2.94 (1.59,4.01) 22 % 2.60 (1.40,3.52) 17 % 1.58 (0.54,2.73) 28 %
PI-Based 2.66 (1.58,3.51) 30 % 2.62 (1.70,3.43) 24 % 1.31 (0.42,2.36) 41 %
Other 2.95 (1.95,3.69) 18 % 2.89 (1.93,3.49) 15 % 1.97 (1.11,2.95) 40 %
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lipid measurement, hepatitis C co-infected IDUs had
lower relative rates of creatinine and lipid measurements
(RR = 0.80 and RR = 0.65, respectively) than HIV
mono-infected non-IDUs. Abacavir use was associated
with higher rates of lipid measurements (RR = 1.13,
95 % CI = (1.08, 1.18), p-value < 0.0001).
Twenty-two percent, 18 % and 33 % of participants
had at least one 12 month gap between measurements
of ALT/AST, creatinine and lipid measurements, re-
spectively. In a multivariable GEE model with a logit
link, viral load suppression (<50 copies/mL) at the start
of an inter-test gap (OR = 0.67, 95 % CI = (0.59,0.77),
p < 0.0001) and older age (OR per 10 years = 0.77,
95 % CI = (0.70, 0.84), p < 0.0001) were associated with
decreased risk of a 12 month gap between ALT/AST
measurements while hepatitis C co-infected partici-
pants with a history of IDU were at an increased risk
of a 12 month gap (OR = 2.21, 95 % CI = (1.73,2.82),
p < 0.0001) (Table 4). Similar results were observed
for gaps in creatinine and lipid measurements (Table 4);
however, male gender (OR = 0.77, 95 % CI = (0.63,
0.94), p = 0.01), and a grade 3 or 4 elevation in lipid
measurements (OR = 0.68, 95 % CI = (0.54, 0.86), p < 0.01)
were associated with a decreased risk of gap between lipid
measures, and a grade 3 or 4 elevation in ALT/AST
measurement was associated with a decreased risk of
a gap between ALT/AST measurements (OR = 0.64,
95 % CI = (0.44,0.93), p = 0.02). Results were similar
for gaps in excess of 18 months; with the exception
that Black race and Grade 3 or 4 levels were no lon-
ger significantly associated with gaps in lipid mea-
surements (data not shown).
Discussion
In this cohort of people infected with HIV from across
Canada who had initiated cART since 2000, rates of
laboratory test measurement differed by age, race and
HIV risk factor despite access to publicly funded health
care even after adjusting for rate of CD4 measurement
as a surrogate of engagement in care. Persons with HIV-
hepatitis C co-infection and with a history of IDU had
significantly lower rates of measurement of these tests
and were more likely to have a 12 month gap between
measurements than participants without history of IDU
whether or not they were HIV mono- or HIV-hepatitis
C co-infected. However, hepatitis C co-infected partic-
ipants without a history of IDU were not monitored
less frequently than HIV mono-infected individuals, in
concordance with clinical guidelines [5, 9].
Our results are similar to those of a multi-site study
from the United States of HIV-positive individuals initi-
ating cART, where older age, lower CD4 count, an AIDS
diagnosis, later year of cART initiation, boosted PI-based
cART regimens and Abacavir use were associated with
shorter times to both the first laboratory test and
repeated laboratory tests [11]. As in our study, liver
enzyme and renal function measurements were more
frequent than lipid measurements [11]. However, the
study by Yanik et al observed higher rates of liver
enzyme and renal function measurement than our study
(with annual rates of 5.14 within the first 6 months and
3.39 between 6 and 36 months for liver enzymes, and
5.00 and 3.36, respectively, for renal function), but with
lower rates of lipid testing [11]. The differences in rates
of measurement may be due to study design. Yanik et al
[11] included participants with at least one laboratory
measurement and censored patients at the time of treat-
ment switch or discontinuation and occurrence of ab-
normal laboratory result, resulting in a median duration
of follow-up of 11 months. In our analyses, we counted
only one measurement per month to avoid inflated rates
due to repeat testing during hospitalization. As in Yanik’s
Table 2 Median rate of measurement and probability of having a gap greater than 12 months between measurements of liver,
renal or metabolic function (Continued)
Hepatitis C co-infection
HCV+ 2.38 (0.90,3.86)*** 36 %*** 1.82 (0.55,3.32)*** 28 %*** 0.88 (0.14,2.08)*** 35 %
HCV- 2.82 (1.77,3.73) 19 % 2.63 (1.67,3.39) 15 % 1.52 (0.60,2.60) 32 %
Hepatitis B co-infection
HBV+ 2.73 (1.49,3.45) 17 % 2.63 (1.51,3.30) 18 % 1.41 (0.59,2.37) 35 %
HBV- 2.69 (1.74,3.55) 20 % 2.65 (1.80,3.43) 16 % 1.50 (0.59,2.50) 36 %
HCV and IDU status
HCV- non-IDU 2.89 (1.89,3.79)*** 20 %*** 2.68 (1.81,3.45)*** 16 %*** 1.45 (0.60,2.49)*** 36 %***
HCV+ non-IDU 3.31 (2.02,4.54) 25 % 3.12 (1.76,4.29) 18 % 1.78 (0.70,3.18) 34 %
HCV- IDU 2.90 (1.46,4.08) 23 % 2.30 (1.01,3.25) 15 % 1.21 (0.49,2.32) 23 %
HCV+ IDU 1.83 (0.62,3.60) 42 % 1.34 (0.27,2.93) 33 % 0.52 (0.00,1.42) 37 %
Unknown 2.45 (1.34,3.39) 17 % 2.34 (1.31,3.20) 16 % 1.75 (0.57,2.83) 24 %
IDU injection drug use as risk factor for HIV acquisition, HCV+: positive for Hepatitis C; * = <0.01, ** = <0.001, *** = <0.0001
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study, we noted slightly higher rates of measurement in
the first year after initiation of cART.
In our previous work examining factors associated with
rates of viral load (VL) measurement among CANOC par-
ticipants, geographic region, HIV risk factor, age, year of
cART initiation, type of cART regimen, being in the first
year of cART, AIDS defining illness and whether or not
the previous VL was below the limit of detection were
associated with lower rates of VL measurement and gaps
in VL measurement of more than 9 months [12]. We have
also reported findings from a study of HIV-positive indi-
viduals in Ontario, Canada, wherein younger individuals,
injection drug users and residents of Toronto had lower
rates of VL measurement [13].
Our observations within the current study suggest that
challenges in HIV care engagement among people with a
Table 3 Multivariable analysis of prognostic factors for rate of laboratory measurement according to zero-inflated negative binomial
models
Liver (AST/ALT) Renal (Creatinine) Metabolic (Lipids)
(N = 3934) (N = 3530) (N = 3530)
Rate ratio 95 % CI p-value Rate ratio 95 % CI p-value Rate ratio 95 % CI p-value
Negative binomial
Province
British Columbia Ref Ref Ref
Ontario 0.98 (0.94,1.03) 0.48 1.35 (1.29,1.42) <0.0001 1.13 (1.05,1.21) <0.001
Quebec 1.20 (1.13,1.27) <0.0001 1.70 (1.60,1.80) <0.0001 1.45 (1.34,1.57) <0.0001
Age (per 10 years) 1.02 (1.00,1.04) 0.03 1.03 (1.01,1.05) <0.01 1.05 (1.02,1.08) 0.0001
Male 1.02 (0.98,1.07) 0.37 1.01 (0.96,1.06) 0.72 1.14 (1.07,1.22) 0.0001
Race
Caucasian Ref Ref Ref
Black 1.03 (0.97,1.10) 0.37 0.93 (0.86,1.00) 0.04 0.80 (0.72,0.89) <0.0001
Aboriginal 0.87 (0.79,0.96) <0.01 0.87 (0.79,0.97) <0.01 0.84 (0.72,0.97) 0.02
Other 1.11 (1.04,1.18) <0.01 1.09 (1.02,1.16) <0.01 1.06 (0.97,1.16) 0.19
Unknown 0.89 (0.85,0.93) <0.0001 0.92 (0.88,0.96) <0.001 0.76 (0.71,0.81) <0.0001
HCV and IDU status
HCV-non-IDU Ref Ref Ref
HCV+ non-IDU 1.05 (0.97,1.14) 0.21 1.07 (0.99,1.15) 0.09 1.00 (0.89,1.12) 0.99
HCV-IDU 0.98 (0.89,1.07) 0.62 0.95 (0.87,1.05) 0.31 0.95 (0.83,1.08) 0.43
HCV+ IDU 0.79 (0.74,0.83) <0.0001 0.80 (0.75,0.85) <0.0001 0.65 (0.59,0.71) <0.0001
Unknown 0.97 (0.93,1.02) 0.21 1.00 (0.96,1.04) 0.96 1.28 (1.20,1.36) <0.0001
CD4 measurements:
<3 per year Ref Ref Ref
3-5 per year 1.87 (1.79,1.95) <0.0001 1.76 (1.68,1.84) <0.0001 1.84 (1.73,1.97) <0.0001
≥6 per year 2.67 (2.52,2.83) <0.0001 2.56 (2.41,2.71) <0.0001 2.79 (2.56,3.03) <0.0001
First cART regimen
Other Ref Ref Ref
NNRTI based 0.95 (0.86,1.05) 0.32 0.97 (0.88,1.06) 0.47 0.78 (0.68,0.90) <0.001
Boosted PI based 0.96 (0.87,1.07) 0.48 1.01 (0.91,1.11) 0.89 0.88 (0.77,1.02) 0.08
PI based 0.95 (0.85,1.05) 0.32 0.95 (0.86,1.05) 0.35 0.78 (0.67,0.90) <0.001
Abacavir use – – – – – 1.13 (1.08,1.18) <0.0001
Tenofovir use – – – 0.99 (0.96,1.03) 0.68 – – –
Zero-inflated
IDU 0.19 (0.11,0.32) <0.0001 0.22 (0.15, 0.34) <0.0001 0.17 (0.11,0.26) <0.0001
Unknown HIV risk factor 1.32 (0.50,3.48) 0.58 1.14 (0.59,2.19) 0.70 0.96 (0.43,2.14) 0.92
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history of IDU may considerably limit the ability to fol-
low clinical guidelines for laboratory testing in this
population. Previously we have shown that participants
with a history of IDU in CANOC were more likely to be
suboptimally engaged in HIV care [14], consistent with
our present finding of lower rates of laboratory monitor-
ing in this subpopulation. A review paper by Wood et al
[15] found barriers to care for IDUs included psychiatric
illness, financial constraints inhibiting travel to and from
clinic, physician perceptions and inexperience with pa-
tients with substance use issues, incarceration, and
homelessness. Wood et al also found that hepatitis C
co-infection was associated with less treatment access
for IDU, consistent with our findings that hepatitis C
co-infected IDU had the lowest rates of laboratory marker
measurement and were significantly more likely to have
clinically important gaps in measurement than both HIV
mono-infected and hepatitis C co-infected non-IDU, and
even HIV mono-infected IDU.
The EACS and BC CfE guidelines specifically suggest
increased frequency of monitoring for liver and renal
function abnormalities for those co-infected with hepa-
titis C [5, 9]. As such, the disparity in the frequency of
clinical monitoring of laboratory markers between
hepatitis C co-infected participants with a history of
IDU and those without a history of IDU is concerning.
Although hepatitis C acquisition has occurred among
people who do not inject drugs [16, 17] and such
Table 4 Multivariable Generalized Estimating Equation (GEE) models of a gap of 12 months between laboratory measurements
Liver (AST/ALT) Renal (Creatinine) Metabolic (Lipids)
(N = 3343) (N = 2955) (N = 2838)
Odds ratio 95 % CI p-value Odds ratio 95 % CI p-value Odds ratio 95 % CI p-value
Province
British Columbia Ref Ref Ref
Ontario 1.03 (0.82,1.30) 0.79 0.95 (0.71,1.28) 0.74 2.78 (2.16,3.58) <0.0001
Quebec 0.99 (0.74,1.32) 0.94 1.18 (0.86,1.61) 0.31 2.56 (1.96,3.33) <0.0001
Age at cART initiation (per 10 years) 0.77 (0.70,0.84) <0.0001 0.73 (0.66,0.81) <0.0001 0.87 (0.80,0.96) <0.01
Male 0.92 (0.74,1.15) 0.46 0.97 (0.74,1.28) 0.84 0.77 (0.63,0.94) 0.01
Race
Caucasian Ref Ref Ref
Black 1.43 (1.05,1.96) 0.02 1.09 (0.69,1.73) 0.71 1.78 (1.29,2.45) <0.001
Aboriginal 1.09 (0.73,1.64) 0.66 0.80 (0.48,1.33) 0.38 1.22 (0.75,1.96) 0.42
Other 0.52 (0.35,0.75) <0.001 0.55 (0.35,0.85) <0.01 0.92 (0.65,1.30) 0.62
Unknown 1.18 (0.92,1.52) 0.19 0.90 (0.69,1.18) 0.44 1.10 (0.90,1.35) 0.36
HCV and IDU status
HCV- non-IDU Ref Ref Ref
HCV+ non-IDU 0.98 (0.67,1.43) 0.92 0.83 (0.52,1.33) 0.44 0.72 (0.50,1.03) 0.07
HCV- IDU 1.02 (0.65,1.60) 0.92 1.04 (0.59,1.82) 0.89 0.86 (0.51,1.45) 0.58
HCV+ IDU 2.21 (1.73,2.82) <0.0001 1.88 (1.40,2.53) <0.0001 1.70 (1.30,2.23) <0.001
Unknown 1.15 (0.88,1.49) 0.30 1.47 (1.12,1.93) 0.01 0.55 (0.44,0.68) <0.0001
Grade 3 or 4 elevation at previous visit 0.64 (0.44,0.93) 0.02 1.74 (0.51,5.96) 0.38 0.68 (0.54,0.86) <0.01
VL < 50 copies/mL at gap start 0.67 (0.59,0.77) <0.0001 0.63 (0.52,0.75) <0.0001 0.82 (0.72,0.93) <0.01
CD4 count at gap start
<200 cells/mm3 Ref Ref Ref
200-350 cells/mm3 0.92 (0.77,1.10) 0.35 1.07 (0.85,1.35) 0.55 1.02 (0.87,1.20) 0.80
350-500 cells/mm3 0.88 (0.72,1.07) 0.18 1.08 (0.83,1.39) 0.58 1.11 (0.93,1.33) 0.26
>500 cells/mm3 1.03 (0.84,1.26) 0.76 1.26 (0.97,1.63) 0.09 1.12 (0.93,1.35) 0.23
cART initiation year
2000 Ref Ref Ref
2001-2005 0.56 (0.45,0.70) <0.0001 0.58 (0.44,0.77) 0.0001 0.83 (0.64,1.08) 0.16
>2005 0.37 (0.29,0.48) <0.0001 0.39 (0.28,0.54) <0.0001 0.72 (0.55,0.94) 0.02
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individuals were not at increased risk of gaps in meas-
urement, the majority of HIV-hepatitis C co-infected
individuals have IDU as a risk factor. These individuals
have elevated risk of liver and kidney disease, yet are
monitored less frequently for the development of such
comorbid conditions.
When interpreting studies of liver or renal toxicity or
the development of comorbid conditions, differential
monitoring needs to be considered, as abnormalities are
likely to be detected sooner in individuals monitored
more frequently [18]. If monitoring patterns are inform-
ative, estimates of the association of covariates on rates
of adverse events may be biased [18]. Where appropri-
ate, analyses which adjust for differential rates of meas-
urement should be employed; these include marginal
structural models for dynamic observation plans [19],
interval censoring methods [18], and discrete time
survival methods [20]. Explicit discussion of bias intro-
duced from differential monitoring should be discussed if
technical limitations preclude the use of these methods.
Strengths of this analysis include the size and diversity
of the CANOC cohort, which captures approximately
half of the HIV-positive individuals who have initiated
cART since 2000 in Canada [10]. The publicly funded
health care setting allowed us to assess factors associated
with rates of measurement of laboratory markers in the
absence of financial barriers directly related to the
laboratory test and incurred by the patient. Nevertheless,
there are potential limitations that merit consideration
which relate to potential information bias. We did not
have access to data on risk factors for comorbid condi-
tions such as family history of illness, smoking and body
mass index, all of which would influence clinical
decision-making regarding the frequency of laboratory
monitoring. Further, as some CANOC sites specialize in
HIV care, our rates of laboratory monitoring may be
underestimated because some patients may be moni-
tored by their primary care physicians. Analyses of data
from both HIV care sites and primary care sites would
allow a more complete picture of monitoring of co-
morbidities. Nevertheless, we do not believe that such
absence of data would affect our conclusions as Abo-
riginal peoples and IDU also face barriers to accessing
primary care [21–23].
Conclusions
Despite a publicly funded health care setting, there were
disparities in the frequency of liver, renal, and metabolic
function laboratory monitoring among subpopulations
of HIV-positive individuals. Liver enzymes were more
commonly and routinely measured than renal function
and lipid tests, and frequency of monitoring differed by
age, race, HIV risk factor, and history of hepatitis C
co-infection. In particular, people with hepatitis C co-
infection and a history of IDU had the lowest rates of
laboratory marker measurement despite being at higher
risk for cirrhosis and end-stage kidney disease. Further
research should evaluate the clinical impact of delayed
detection of laboratory abnormalities on the development
of comorbid conditions.
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